Oriola-KD makes changes to management team

Henry Fogels adds acting director general of wholesale business in Russia to his duties

Henry Fogels, general director of Oriola-KD's Pharmaceutical Retail business in Russia (OOO Vitim) has been nominated, in addition to his current duties, to the position of acting general director of Oriola-KD's Pharmaceutical Wholesale business in Russia.

Fogels will continue as a member of Oriola-KD's Group Management Team, being responsible for Oriola-KD's businesses in Russia.

Fogels has replaced Vladimir Knyazev, who left the Espoo, Finland-based company this month.

You may also like

Manufacturing

Oriola-KD to sell healthcare trade business to Mediq

Dutch firm to acquire Oriola-KD businesses across Scandinavia and Europe
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Subscribe now